All In Biotech

Drug Trial Radar · NCT05934253

The Effects of Low Viscosity Chloroprocaine Ophthalmic Gel 3% on the Bactericidal Action of Povidone-Iodine

The Effects of Low Viscosity Chloroprocaine Ophthalmic Gel 3% on the Bactericidal Action of Povidone-Iodine: A Comparison vs Tetracaine 0.5% Solution.

Last checked: Nov 20, 2026Latest source record: Sep 16, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 100 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

100

Actual

Start

Jul 15, 2023

Primary completion

Jan 15, 2024

Study completion Feb 15, 2024

Sponsor

Lead sponsor
Harrow IncIndustry
Sponsor type
Industry
First posted
Jul 6, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Crossover
Masking
Double (participant, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 99 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

To evaluate if Iheezo's (chloroprocaine 3%) gel vehicle acts as a barrier on the ocular surface, potentially blocking the bactericidal action of povidone-iodine.

Conditions

  • Antiseptic
  • Anesthesia, Local

Interventions

  • Chloroprocaine ophthalmic gel 3%Drug

    FDA approved topical ophthalmic anesthetic applied 3 drops to the ocular surface before the planned procedure.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in colony forming unitsTime frame: Baseline and 5 minutes after baseline.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Brandon Eye Associates

    Brandon, Florida

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.